The maker of the popular diabetes drug Ozempic has taken legal action against a competitor, accusing it of running false advertisements. Novo Nordisk filed a lawsuit against Eli Lilly, claiming that its rival’s marketing for similar medications is misleading. The case centers on ads that Novo Nordisk says give a wrong impression about the safety or effectiveness of its products.
Eli Lilly has denied the allegations. A company spokesperson said that the claims are without merit and that its advertising is truthful and accurate. The lawsuit is the latest development in a fierce competition between the two pharmaceutical giants, both of which sell drugs for diabetes and weight loss. Ozempic and Eli Lilly’s Mounjaro are among the most prescribed treatments in this category.
Legal experts say the case could have significant implications for how drug companies market their products. Novo Nordisk is asking the court to stop the allegedly misleading ads and to seek damages. A trial date has not yet been set.
This dispute highlights the high stakes in the weight-loss drug market, which has exploded in popularity over the past year. Both companies are spending heavily on advertising to capture a larger share of the growing demand.